RESEARCH IN PULMONARY HYPERTENSION
"PHA's research program has yielded an explosion of understanding about PH that was not known before."
- John Newman, MD, Vanderbilt University Medical Center
Twenty years ago there were no pulmonary hypertension treatments available. Through focused research there are now twelve PH-specific treatments with more in development. But we know that your ultimate wish is for a cure, and that is why PHA will continue to support the work of researchers until the day when no one suffers from PH.
PHA’s Research Program
In just a little under a decade, PHA’s Research Program has committed more than $12.5 million for PH research by leveraging partnerships with the National Heart, Lung, and Blood Institute (NHLBI) and the American Thoracic Society (ATS). We have supported over 49 promising researchers through four independently reviewed, cutting-edge research programs.
Read more about PHA’s Research Program
PHA’s Scientific Leadership Council’s Education Committee has put together comprehensive factsheets on all the treatments available for pulmonary hypertension. Read more about current treatments
Research Corner in Pathlight
Every issue of PHA’s quarterly print newsletter Pathlight features a Research Corner with information about some of the latest research. Read more
Pulmonary Hypertension Research News
PHA's Research Room: Leaving Your Mark in the Future of PH
PHA's International PH Conference and Scientific Sessions includes a Research Room dedicated to helping researchers further their studies by allowing for the collection of data from PH patients, as well as their family and friends. This event gives researchers the rare opportunity to collect data from the largest gathering of patients and families living with PH in the world.
Join this webinar to learn about past Research Room successes, and what individuals planning to participate in the Research Room may expect. While patient participation is valuable, there is often the opportunity for family and friends to participate as well.
- Eric Austin, MD, MSCI
- Micheala Aldred, PhD
- Wendy Chung, MD, PhD
- C. Gregory Elliott, MD
Friday, April 18, 2014 11:00:00 AM
World PH Day Webinar on New PH Treatments
Join us April 29 at 12 p.m. ET/9 a.m. PT for Dr. Michael McGoon’s popular annual webinar “PH Treatments: What’s on the Horizon.” This one-hour webinar will cover the new treatments recently approved by the FDA, as well as look at treatments in the pipeline for approval in the coming years.
Thursday, April 17, 2014 5:00:00 PM
FDA Meeting Registration Deadline Just Two Weeks Away
On May 13, in White Oak, Md., the Food and Drug Administration will host an informal, “talk show” style meeting where PAH patients can share what it’s really like to live with pulmonary arterial hypertension. FDA will use this information when considering whether to approve PH drugs in the future.
Please help us make a better tomorrow for PAH patients by attending in person or listening in and submitting comments via webcast. Register by April 30.
- Register with FDA. Whether you are attending in person or by webcast, you must register on FDA’s website. All members of the PH community are welcome, but PAH patients and the parents of young patients will do the talking.
- Claim your seat on the bus. For those who would prefer not to drive to the FDA campus, buses are available from pick up points in New York, Philadelphia and Maryland.
Don't miss out on this unique opportunity!
Questions? Contact Katie at 301-565-3004 x749.
Wednesday, April 16, 2014 6:00:00 PM
PROMIS Quality of Life Survey
Vivek Nagaraja, MD and Dinesh Khanna, MD, MSc at the University of Michigan Health System, are conducting a piece of research called PROMIS (Patient Reported Outcomes Measurement Information System) in rheumatology. The research involves an online survey catered to patients with various rheumatologic conditions. Interested patients are highly encouraged to take this survey as it provides important information about the burden of their rheumatologic condition on different aspects of life. This survey is completely voluntary and confidential.
Click here to take the survey: www.Bitly.com/UMpromis
View further instructions on taking the survey: www.PHAssociation.org/PROMIS_Survey_Instructions
Thursday, April 10, 2014 4:52:00 PM
Bayer Begins Riociguat Trial for Resistant PAH
healio - Bayer HealthCare announced enrollment of the first participant in the phase 3b RESPITE study. The open-label, multicenter, international pilot study will assess the soluble guanylate cyclase stimulator riociguat (Adempas) in patients with pulmonary arterial hypertension who are resistant to treatment with phosphodiesterase-5 (PDE5) inhibitors.
Monday, April 07, 2014 11:00:00 PM